Apellis soars as Alexion rival outshines blockbuster standard bearer Soliris — then fresh doubts scuttle spike
Apellis went gunning for Alexion’s star drug Soliris in a head-to-head PNH Phase III. And the smaller biotech said Tuesday morning that they came out with a clear win.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.